Importance of breast cancer subtype in the development of androgen-receptor-directed therapy

Current Breast Cancer Reports

Volumn 6, Issue 2, 2014, Pages 71-78

  Lim, Elgene ^a   Ni, Min ^a   Cao, Shiliang ^a   Hazra, Aditi ^b   Tamimi, Rulla M ^b   Brown, Myles ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Androgen receptor; Androgen receptor directed therapy; Breast cancer; Breast cancer subtype

Indexed keywords

EID: 84905725004     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-014-0140-5     Document Type: Review

References (59)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747- 52.
2. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
3. • Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011;24(7):924-31. One of the largest studies of androgen receptor (AR) expression in primary breast cancers using the Nurses Health Study tumor microarray resource, comparing AR expression according to the different breast cancer subtypes.
4. • Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011;17(7):1867-74. This is one of the first reports studying the effect of AR expression on breast cancer outcomes in post-menopausal women according to breast cancer subtype.
5. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, et al. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008;13(5):431-5.
6. Walters KA, Simanainen U, Handelsman DJ. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update. 2010;16(5):543-58.
7. Zhou X. Roles of androgen receptor in male and female reproduction: lessons fromglobal and cell-specific androgen receptor knockout (ARKO) mice. J Androl. 2010;31(3):235-43.
8. Nicolas Diaz-Chico B, German Rodriguez F, Gonzalez A, Ramirez R, Bilbao C, Cabrera de Leon A, et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol. 2007;105(1-5):1-15.
9. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24(2):152-82. (Pubitemid 36515283)
10. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas. 2009;63(2):142-8.
11. • Key TJ, Appleby PN, Reeves GK, Travis RC, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013;14(10):1009-19. A pooled analysis with data for 767 women with breast cancer and 1699 controls, that revealed that circulating estrogens and androgens are positively associated with the risk of breast cancer in premenopausal women.
12. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat. 2013;137(3):883-92.
13. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12(4):1071-82. (Pubitemid 41815798)
14. Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast Cancer Collaborative G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-16. (Pubitemid 34498648)
15. • Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, et al. Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2013. A meta-analysis of 19 studies including a total of 7693 women with early breast cancer that revealed expression of AR in women with breast cancer is associated with better OS and DFS irrespective of coexpression of ER.
16. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009;15(7):2472-8.
17. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124(3):607-17.
18. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69(15):6131-40.
19. Lim E, Ni M, Hazra A, Tamimi RM, Brown M. Elucidating the role of the Androgen Receptor in breast cancer. Clin Investig. 2012;2(10):1003-11.
20. Li S, Han B, Liu G, Li S, Ouellet J, Labrie F, et al. Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem: Off J Histochem Soc. 2010;58(6):509-15.
21. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15(8):907-13.
22. • Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, et al. Taxonomy of Breast Cancers Based on Normal Cell Phenotype. Journal of Clinical Investigation. 2013. This study of the distribution of AR+ cells in normal mammary lobules revealed that AR+ cells were luminal in origin, as defined by the expression of keratins 7 and 18, and claudin-4. There was only a 44% overlap of AR+ cells with ER+ cells, and no overlap with proliferating Ki-67+ cells.
23. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res. 1989;49(24 Pt 1):7162-7. (Pubitemid 20016610)
24. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25(28):3994- 4008. (Pubitemid 43990755)
25. Adams JB, Archibald L, Seymour-Munn K. Dehydroepiandrosterone and androst-5-ene-3 beta,17 beta-diol in human mammary cancer cytosolic and nuclear compartments and their relationship to estrogen receptor. Cancer Res. 1980;40(10):3815-20. (Pubitemid 10003795)
26. Boccuzzi G, Di Monaco M, Brignardello E, Leonardi L, Gatto V, Pizzini A, et al. Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast cancer cell line. Anticanc Res. 1993;13(6A):2267-72. (Pubitemid 24036361)
27. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol. 2002;80(2):175-89. (Pubitemid 34233739)
28. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrin. 2000;167(1-2):139-50.
29. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121(1):1-11.
30. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66(15):7775-82. (Pubitemid 44289238)
31. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24(26):4236-44. (Pubitemid 46630780)
32. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66(21):10292-301. (Pubitemid 44799747)
33. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365(9460):671-9. (Pubitemid 40260888)
34. •• Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20(1):119-31. This study provides evidence that AR is enriched in ER-breast tumors that overexpress HER2, and that AR mediates ligand-dependent activation of Wnt and HER2 signaling pathways through the direct transcriptional induction of WNT7B and HER3. Specific targeting of AR, Wnt, or HER2 signaling impairs androgen-stimulated tumor-cell growth, suggesting potential therapeutic approaches for ER-/HER2+breast cancers.
35. Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genom. 2009;2:59.
36. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27(7):734-48.
37. Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia. 2011;13(2):154-66.
38. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 2003;120(5):725-31. (Pubitemid 37339680)
39. McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ, Nunez-Nateras R, et al. Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. Ann Surg Oncol. 2013.
40. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25-32. (Pubitemid 46120191)
41. • Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505-12. This is a recently completed phase II trial of bicalutamide for advanced TNBC, which reported a clinical benefit rate of 19%, and a median progression-free survival of 12 weeks.
42. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;130(2):477-87.
43. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol. 2012;29(2):406-10.
44. •• Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinicalmodels for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. Describes six triple-negative breast cancer subtypes with unique gene expression and ontologies, including a luminal AR subtype characterized by AR signaling, PIK3CA mutations, and sensitivity to bicalutamide.
45. Yu KD, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013;19(10):2723-33.
46. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
47. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-90.
48. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-503.
49. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999;59(11):2511-5. (Pubitemid 29269089)
50. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, et al. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat. 2006;98(2):217-22. (Pubitemid 44050772)
51. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 1991;67(4):886-91.
52. Rose C, Kamby C, Mouridsen HT, Andersson M, Bastholt L, Moller KA, et al. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. Arandomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Res Treat. 2000;61(2):103-10.
53. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med. 2013;368(15):1458-9.
54. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-48.
55. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335-45.
56. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med: Off Publ, Soc Nucl Med. 2004;45(3):366-73. (Pubitemid 47618608)
57. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imag. 2005;32(3):344-50. (Pubitemid 40562127)
58. Beattie BJ, Smith-Jones PM, Jhanwar YS, Schoder H, Schmidtlein CR, Morris MJ, et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro- 5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med: Off Publ, Soc Nucl Med. 2010;51(2):183-92.
59. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437-46.